ABVX Stock Risk & Deep Value Analysis
Abivax SA
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ABVX Stock
We analyzed Abivax SA using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABVX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ABVX Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is that the Phase 3 topline data for obefazimod in Ulcerative Colitis, expected late Q2 2026, could be disappointing, failing to demonstrate sufficient efficacy or a superior safety profile compared to existing therapies. This would severely impact the NDA filing, market potential, and could lead to a significant stock price devaluation.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Widening net losses to €336.1M in FY 2025, with persistent high cash burn.
- ⚠
Significant share dilution from the €597.2M capital raise in 2025, impacting per-share value.
- ⚠
Stretched pre-revenue valuation ($8.31B market cap) implies substantial success is already priced in, leaving little room for error.
- ⚠
High R&D expenses (€177.8M in FY 2025) which are necessary but contribute to the cash burn.
Upcoming Risk Events
- 📅
Disappointing Phase 3 topline results for obefazimod in UC (late Q2 2026)
- 📅
Regulatory hurdles or unexpected delays in NDA review
- 📅
Failure to achieve anticipated market penetration post-launch
When to Reconsider
- 🚪
Exit if Phase 3 topline results for obefazimod are negative or substantially below expectations.
- 🚪
Sell if the company announces further significant delays in the NDA filing timeline or faces unexpected regulatory setbacks.
- 🚪
Exit if cash runway significantly shortens due to accelerated burn rates without clear financing plans.
Unlock ABVX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Abivax SA (ABVX) Do?
Market Cap
$8.31B
Sector
Healthcare
Industry
Biotechnology
Employees
69
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Visit Abivax SA WebsiteInvestment Thesis
Abivax offers high-risk, high-reward potential driven by obefazimod, a promising first-in-class oral STAT1 inhibitor for Ulcerative Colitis and Crohn's Disease. With Phase 3 UC trials nearing completion and a strong cash position, positive clinical data and subsequent regulatory approval could unlock substantial value, positioning the company for significant market penetration in a multi-billion dollar inflammatory bowel disease market.
Is ABVX Stock Undervalued?
Unlock the full AI analysis for ABVX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ABVX Price Targets & Strategy
12-Month Target
$180.00
Bull Case
$250.00
Bear Case
$70.00
Valuation Basis
Re-rating to 1.5x estimated peak sales potential for obefazimod across UC/CD (~$8-10B combined) post-Phase 3 success and NDA filing.
Entry Strategy
Dollar-cost average on dips towards key support levels (e.g., $100-$110 range), especially ahead of or following positive catalysts. Avoid chasing significant rallies post-news.
Exit Strategy
Take partial profits around $180-$200 following Phase 3 topline results and NDA filing. Consider a stop-loss order if negative data emerges or price falls below $100.
Portfolio Allocation
5-10% for aggressive risk tolerance (given pre-revenue nature and high reliance on single asset).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ABVX Financially Healthy?
Valuation
P/E Ratio
-19.08
Profitability
Return on Equity
-211.43%
EPS
$-3.91
Balance Sheet
Current Ratio
1.82
Quick Ratio
1.78
Debt/Equity
2.37
Other
Beta (Volatility)
1.09
Does ABVX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability depends heavily on the strength of obefazimod's clinical data, regulatory approvals, and sustained patent protection. If the drug proves to be a highly effective and safe oral treatment, it could command a strong market position for the duration of its patent life.
Moat Erosion Risks
- •Emergence of superior or equally effective competing therapies with better safety profiles or lower costs.
- •Patent challenges or expiry, leading to generic competition.
- •Failure to achieve broad market adoption due to commercialization challenges or physician preference for established treatments.
ABVX Competitive Moat Analysis
Sign up to see competitive advantages
ABVX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data provided, but biotech trials often generate retail interest).
Institutional Sentiment
Positive (8 analysts rate 'Accumuler', indicating a mix of Hold/Buy recommendations).
Insider Activity (Form 4)
New Chief Commercial Officer Michael Nesrallah appointed, Chief Scientific Officer departed. No Form 4 filings reported in results (Jan 15-Apr 15, 2026) for transactions.
Options Flow
Normal options activity (no specific data provided).
Earnings Intelligence
Next Earnings
2026-05-25 (Q1 2026)
Surprise Probability
Medium (as a clinical-stage biotech, focus is on pipeline updates rather than traditional revenue beats).
Historical Earnings Pattern
Biotech stocks often react significantly to clinical trial updates and regulatory news rather than quarterly financial results, particularly for pre-revenue companies. Price movements around earnings are usually driven by pipeline commentary.
Key Metrics to Watch
Competitive Position
Top Competitor
AbbVie (ABBV)
Market Share Trend
Currently 0%, but has significant potential to gain market share in the UC/CD treatment landscape if obefazimod is approved.
Valuation vs Peers
Trading at an extreme premium on EV/Revenue (3,030x 2026E, 66.7x 2027E) compared to established, profitable biotech/pharma peers, which is typical for a pre-revenue, late-stage clinical company. This indicates high market expectations for future sales.
Competitive Advantages
- •First-in-class oral STAT1 inhibitor mechanism of action (MOA)
- •Potential for differentiated efficacy and safety profile in UC/CD
- •Strong intellectual property protection for obefazimod
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ABVX Stock Higher?
Near-Term (0-6 months)
- •ABTECT-UC Phase 3 (maintenance) topline results (late Q2 2026)
- •Q1 2026 Earnings report (May 25, 2026)
- •NDA filing for Obefazimod in UC (Q4 2026, if positive Phase 3 results)
Medium-Term (6-18 months)
- •Phase 2b CD induction results (Q4 2026)
- •Potential EU marketing authorization application filing for UC (2027)
- •Commercial launch of Obefazimod in US/EU (2027-2028)
Long-Term (18+ months)
- •Expansion into additional inflammatory indications (beyond UC/CD)
- •Establishment as a market leader in oral IBD therapies
- •Pipeline development beyond obefazimod
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABVX?
- ✓
Strong efficacy and safety data from obefazimod's Phase 3 UC topline results.
- ✓
Successful and timely NDA filing and subsequent regulatory approval for UC.
- ✓
Positive Phase 2b data for Crohn's Disease, indicating label expansion potential.
Bull Case Analysis
See what could go right with Premium
Competing with ABVX
See how Abivax SA compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Abivax SA ABVX | $8.3B | 7.6 | -19.1 | $520,000 | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Abivax SA Makes Money
Abivax SA is a clinical-stage biotechnology company that focuses on developing novel immune-modulating therapies for chronic inflammatory diseases. Currently, its primary business involves conducting research and development for its lead drug candidate, obefazimod, in late-stage clinical trials for Ulcerative Colitis (UC) and Crohn's Disease (CD). The company is pre-revenue from drug sales and relies on capital raises and collaborations to fund its extensive R&D efforts. If obefazimod receives regulatory approval, its business model will pivot to commercializing and selling the drug to patients through healthcare systems globally, generating revenue from product sales.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Abivax SA (ABVX)?
As of April 15, 2026, Abivax SA has a DVR Score of 7.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Abivax SA?
Abivax SA's market capitalization is approximately $8.3B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Abivax SA use?
ABVX is the ticker symbol for Abivax SA. The company trades on the NGM.
What is the risk level for ABVX stock?
Our analysis rates Abivax SA's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABVX?
Abivax SA currently has a price-to-earnings (P/E) ratio of -19.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the ABVX DVR analysis updated?
Our AI-powered analysis of Abivax SA is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABVX (Abivax SA) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.